Humacyte (HUMA) Change in Accured Expenses (2020 - 2026)
Humacyte (HUMA) reported Change in Accured Expenses of -$2.2 million for Q1 2026, up 3.66% year-over-year from -$2.1 million in Q1 2025, and down 730.42% quarter-over-quarter from -$263000.0 in Q4 2025.
Humacyte (HUMA) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 7 years of Change in Accured Expenses data on file, last reported at -$2.2 million in Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$2.2 million, up 3.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.6 million (down 178.25% YoY), and the FY2025 annual result was -$1.7 million, down 176.36% from the prior year.
- Change in Accured Expenses eased to -$2.2 million in Q1 2026 per HUMA's latest filing, from -$263000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $3.3 million in Q3 2023 and troughed at -$2.3 million in Q1 2025.
- A 5-year average of $19941.2 and a median of -$136000.0 in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses plunged 318.72% in 2022, then soared 1585.04% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at -$1.4 million in 2022, then soared by 70.18% to -$410000.0 in 2023, then jumped by 162.93% to $258000.0 in 2024, then slumped by 201.94% to -$263000.0 in 2025, then sank by 730.42% to -$2.2 million in 2026.
- Business Quant data shows HUMA's Change in Accured Expenses at -$2.2 million in Q1 2026, -$263000.0 in Q4 2025, and $957000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Humacyte | 183.21 Mn | 134.67 Mn | -1.54 Mn | -2.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.18 Mn |
| Mar 31, 2026 | -2.18 Mn |
| Dec 31, 2025 | -263,000.00 |
| Dec 31, 2025 | -263,000.00 |
| Sep 30, 2025 | 957,000.00 |
| Sep 30, 2025 | 957,000.00 |
| Jun 30, 2025 | -136,000.00 |
| Jun 30, 2025 | -136,000.00 |
| Mar 31, 2025 | -2.27 Mn |
| Mar 31, 2025 | -2.27 Mn |
| Dec 31, 2024 | 258,000.00 |
| Dec 31, 2024 | 258,000.00 |
| Sep 30, 2024 | 2.20 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Mar 31, 2024 | -2.11 Mn |
| Mar 31, 2024 | -2.11 Mn |
| Dec 31, 2023 | -410,000.00 |
| Dec 31, 2023 | -410,000.00 |